# Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma

Source: https://onco.cc/trials/nct07047001/  
OnCo record `nct07047001` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Vorolanib in Renal cell carcinoma, run by Dong Wen, active and no longer recruiting.

## Summary

Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma is a phase 2 interventional study registered as NCT07047001 by Dong Wen, with 60 participants planned, started 2025-04-24 and due to reach its primary completion in 2029-06-30. Interventions recorded: Vorolanib Tablets, Vorolanib + Toripalimab. Conditions recorded: Renal Cell Carcinoma (RCC), Adjuvant.

Linked to the drug Vorolanib because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07047001
- Phase: 2
- Setting: The Efficacy and Safety of Vorolanib Monotherapy or in Combination With Toripalimab for Postoperative Adjuvant Treatment of Renal Cell Carcinoma Patients With Intermediate-high Risk Recurrence Factors: A Multicenter, Randomized, Double-arm, Phase II Exploratory Study
- Sponsor: Dong Wen
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07047001: https://clinicaltrials.gov/study/NCT07047001

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Vorolanib](https://onco.cc/drugs/vorolanib/)

---
JSON: https://onco.cc/api/v1/entities/nct07047001.json